 WALTHAM, Mass., May 11, 2021 GLOBE NEWSWIRE -- Minerva Neurosciences, Inc. Nasdaq: NERV, a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced results from the 40-week open-label extension OLE of its phase 3 trial of roluperidone for the treatment of negative symptoms NS of schizophrenia. The OLE followed the 12-week double-blind, placebo-controlled portion of this trial. During the OLE, both investigators and patients were blinded to the roluperidone dose received see About the trial below. 